Company intelligence / Profile preview

Aderis Pharmaceuticals

Virginia, United Statessosnc.gov ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

The company had five product candidates in nine clinical development programs, with some in Phase III trials as of the last available information. One specific clinical trial (NCT00040001) for DTI-0009 was completed, which evaluated safety and efficacy in patients with atrial fibrillation.

Therapeutic areas: CardiovascularNeurologyNephrology
Modalities: Small molecules
Industry: Biotech

Partnerships

Schwarz Pharma AGKing Pharmaceuticals

Beyond the preview

Go deeper on Aderis Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aderis Pharmaceuticals.

Explore the full profile